Johnson and Johnson 2020Q3 results: Strong sales of $21.1 billion in immunology and oncology

, Johnson and Johnson recently released its third quarter 2020 results: sales of $21,082 million, up 1.7 percent from a year earlier, U.S. sales of $11,086 million, up 2.7 percent, and international sales of $9,996 million, up 0.6 percent. Excluding the net impact of acquisitions, divestitures and exchange rate conversions, global sales grew 2.0 per cent, domestic sales in the US rose 2.8 per cent and international sales rose 1.1 per cent. Diluted earnings per share were $1.33, up 101.5 percent from a year earlier, and adjusted diluted earnings per share were $2.20, up 3.8 percent from a year earlier.By business, consumer health business sales of $3.514 billion, pharmaceutical sales of $11.418 billion, medical device business sales of $6.15 billion, excluding the net impact of acquisitions and divestitures, adjusted operations increased 3.1%, 4.7% and decreased 3.3%, respectively, from a year earlier.Driven by the economic recovery and strong momentum and strong business base, Johnson and Johnson raised its full-year forecast sales by $1 billion and earnings per share guidance by $0.15.In the pharmaceutical business, immunology sales were $3,789 million (up 1.9 percent), oncology sales were $3,129 million (up 12.4 percent), and neuroscience sales were $1.605 billion (up 0.4 percent). ), infectious diseases sales of $864 million (up 3.6 percent), pulmonary hypertension sales of $749 million (up 13.9 percent), and cardiovascular and metabolic and other sales of $1,281 million (down 2.5 percent).Among them, the immunology business performed strongly on a number of drugs, including Stelara (up 14.7 per cent), Tremfya (up 13.1 per cent) and Erleada (up 140 per cent), but Remicade fell 18.9 per cent. In addition, there are several drugs in the oncology business that performed very strongly, including Darzalex (up 43.8 per cent) and Imbruvica (up 11.1 per cent), but it is worth noting that Zytiga and Vercado fell by 20.4 per cent and 30.1 per cent, respectively. Opsumit and Uptravi performed strongly in the pulmonary hypertension business, up 14.5 per cent and 13.0 per cent respectively.In the report, Johnson and Johnson also counted pipeline and business updates for the third quarter of 2020:regulatory approval: Thermocool Smarttouch SF ablation catheter approved by the FDA for the treatment of persistent atrial fibrillation; Simponi Aria approved by the FDA for the treatment of polyarthritis in young children aged 2 and over (pJIA) and pneumococid joints PSA; Spravato is FDA approved to treat adult patients with acute suicidal thoughts or behaviors with severe depression (MDD) to rapidly reduce depressive symptoms; Darzalex combination therapy is FDA approved to treat adult patients with recurring or incurable multiple myeloma (R/R MM) who have previously received 1-3 therapies; and Stelara is approved by the FDA to treat pediatric patients with moderate to severe plaque psoriasis.Regulatory submission: Uptravi intravenous preparations were submitted to the FDA for the treatment of pulmonary hypertension (PAH) adult patients; Stelara was treated in pediatric patients with moderate to severe plaque psoriasis (USA); and Darzalex Faspro was submitted to the FDA for the treatment of light chain (AL) amyloid degeneration.Other: Agreement with the European Commission to supply EU member states with 200 million doses of Jansen COVID-19 candidate vaccine; completion of acquisition of Momenta Pharmaceuticals; launch of Janssen COVID-19 vaccine key global Phase 3 clinical trials; and introduction of a new set of new technologies to promote stroke treatment The Jansen COVID-19 vaccine prevents serious clinical diseases in preclinical studies, Jansen terminates the Pimodivir influenza development program, has reached an agreement with the U.S. government to supply 100 million doses of COVID-19 vaccine candidates, and the FDA has granted Ethicon breakthrough equipment qualification.As COVID-19 continues to spread, some people still see the doctor's office as a no-go zone, and clinical trials have been hampered by the COVID-19 pandemic, neither of which is good for pharmaceutical companies, according to the pharmaceutical website Fiercepharma. But Johnson and Johnson outseed the market in pharmaceutical growth in the third quarter of 2020. With the expected launch of new products and strong sales of new branded drugs, the company is confident of growth momentum in 2021.Immunology and oncology performed wellin the third quarter, Johnson and Johnson achieved double-digit growth in seven branded drugs (Erleada, Darzalex, Imbruvica, Stelara, Tremfya, Opsumit, Uptravi). Among them, the immunology business, led by Stelara and Tremfya, had sales of $3.8 billion, making it the company's largest franchise. Cancer drugs, including Erleada, Imbruvica and Darzalex, generated $3.1 billion.However, the situation is not optimistic. Sales of six branded drugs fell compared with the same period last year. The best-selling drugs Remicade and Zytiga continue to compete with generics and biosimilars. Many remain "cautious" about doctors' offices, and fewer visits mean fewer diagnoses and fewer new patients receiving medication. But Johnson and Johnson CFO Joe Wolk said the number of patients expected to increase with the introduction of the COVID-19 vaccine and the spread of treatment.2021 will remain strongJohnson and Johnson expect a larger product lineup in 2021. Its chief financial officer, Joe Wolk, said on a conference call with analysts on Tuesday that Stelara's market penetration in ulcerative colitis and Tremfya's psoriasis arthritis will help keep the immunology business alive in 2021. In addition, the company is planning to submit a listing application for BCMA CAR0T therapy for myeloma and amivantamab for non-small cell lung cancer (NSCLC) in the near future.In the first nine months of 2020, johnson and Johnson's pharmaceutical business reported global sales of $33.3 billion, up 5.2 percent from the same period last year. Overall, Joe Wolk said it expects "strong, capacity-driven growth" in its pharmaceutical business in 2021. Howeverpricing pressures could be an important factor affecting the pharmaceutical industry in 2021. If unemployment remains high in the United States, fewer patients will be covered by commercial insurance, which pays most of the cost of the drug. Separately, U.S. President Donald Trump and Democratic challenger Joe Biden have both pledged to reform drug pricing, an issue that is likely to continue after next month's election. But Jennifer Taubert, chairman of Johnson and Johnson Pharmaceuticals, stressed in a telephone call that the growth in the company's business was "based entirely on capacity, not price."
(
Sina Pharmaceutical News) Reference: 1. Johnson and Johnson Reports 2020 Third-Quarter Results 2. Johnson and Johnson's immunology, blockbusters deliver Q3 and fuel hopes for 2021